Most Popular Angioplasty Web Site
Stent Center Stent Center
with support from Medtronic Cardiovascular
Medtronic Launches Driver Sprint RX Coronary Stent System Worldwide
Design Innovations and Rapid Exchange Contribute to Improved Deliverability

related stories:
Drug-Eluting Stent Center

external sites:
Medtronic, Inc.

Driver stent in vessel
Driver stent in vessel

April 3, 2009 -- Medtronic, Inc. (NYSE: MDT) announced earlier this week that it has begun the international launch of its Driver Sprint RX Coronary Stent System, which received the CE (Conformité Européene) Mark in February 2009. The company plans to have its bare-metal stent on a rapid exchange platform commercially available in more than 100 countries worldwide. “The Driver stent system has always been very deliverable,” explained leading stent researcher Dr. C. Dubois of Leuven University Hospital in Belgium. “Now, the new Driver Sprint system makes it even more deliverable for the most challenging anatomy.”

The new system combines the proven Driver Bare-Metal Stent (BMS), which is already recognized worldwide for being highly deliverable, with an improved delivery system. Specifically, it incorporates a new tip design for a low profile and an enhanced shaft design which together greatly improve the device’s deliverability. These innovations are also incorporated in Medtronic’s Endeavor Sprint and Resolute Drug-Eluting Stent Systems.

The Driver BMS ( is the platform of Medtronic’s coronary stents, which provide physicians with choices to address the spectrum of clinical needs. Its unique modular construction and ultrathin, round, edgeless struts allow for smooth delivery. This design also provides excellent radial strength and high conformability to the vessel wall. More than two million Driver stents have been implanted worldwide since 2002, when the device was first approved for use in clinical practice.

The Driver stent has been thoroughly evaluated in a variety of research settings. The outcomes of more than 3,400 patients followed in both registries and randomized controlled trials have demonstrated the device’s clinical efficacy. Short-term target lesion revascularization (TLR) rates for Driver patients in registries are low, ranging from 3.4 – 9.4 percent at six months and from 6.7 – 7.0 percent at nine months. In addition, nearly 600 Driver patients were followed to four years in ENDEAVOR II, and five-year data from this trial is due for release at EuroPCR in May. The TLR rate for these Driver patients (n=599) at four years is low for a BMS at 15.8 percent.

Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Source: Medtronic, Inc.